Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. My name is Prila, and I'll be your conference operator today.
Halozyme Therapeutics Inc. (HALO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 50,000,000 | $47,665,494 | 0.97% | ||
| 2. | 42,000,000 | $46,770,611 | +212% | 0.02% | |
| 3. | D E Shaw D. E. Shaw | 478,775 | $25,068,659 | +61% | 0.02% |
| 4. | Millennium Management Israel Englander | 423,190 | $22,158,228 | +221% | 0.01% |
| 5. | Renaissance Technologies Jim Simons | 377,580 | $19,770,089 | -13% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | Director | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | Director | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | Director | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | Officer | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | Officer | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $62.58 | 2,037 | 173,756 | 2024-09-18 | Filing | ||
| $61.89 | 7,963 | 175,793 | 2024-09-18 | Filing | ||
| $62.88 | 10,000 | 173,756 | 2024-09-17 | Filing | ||
| $59.20 | 10,000 | 676,744 | 2024-09-12 | Filing | ||
| $59.09 | 10,000 | 676,744 | 2024-09-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,630,963 | $688,600,393 | 0.01% | |
| 2. | 13,259,514 | $490,071,638 | 0.01% | |
| 3. | 6,689,058 | $247,227,584 | 0.38% | |
| 4. | 6,475,549 | $239,336,291 | 0.01% | |
| 5. | 3,709,599 | $142,948,381 | 3.22% |
News See All
Analysts on Wall Street Lower Ratings for These 10 Stocks
Amidst the anticipation surrounding pivotal economic indicators, European futures are on the ascent, signaling a cautious optimism among traders as they prepare for the release of crucial US inflation...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is [Perla] (ph), and I'll be your conference operator today.
How Novo-Catalent Deal Affects Halozyme (HALO)?
Laughing Water Capital, an investment management company, released its first-quarter 2024 investor letter. A copy of the same can be downloaded here.
Should You Hold Halozyme Therapeutics (HALO)?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 5 most undervalued biotech stocks to buy according to hedge funds.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript
Halozyme Therapeutics, Inc. reports earnings inline with expectations. Reported EPS is $0.82 EPS, expectations were $0.82. Halozyme Therapeutics, Inc.
Halozyme Therapeutics (HALO) Underperformed Despite Strong Outlook
Bernzott Capital Advisors, an investment management firm, published its “US Small Cap Value Fund” fourth-quarter 2023 investor letter, a copy of which can be downloaded here.
Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks
In this article, we discuss the 5 stocks receiving price-target cut from analysts.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript
Operator: Hello and welcome to the Halozyme Third Quarter 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise.
Billionaire Hedge Funds
